These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 30050291)

  • 1. Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks.
    Hendin B; Naismith RT; Wray SE; Huang D; Dong Q; Livingston T; Jones DL; Watson C; Jhaveri M
    Patient Prefer Adherence; 2018; 12():1289-1297. PubMed ID: 30050291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Peg IFN Beta-1a (Pre-filled Pen) in Subjects With Relapsing-Remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM Study).
    Centonze D; Fantozzi R; Buttari F; Grimaldi LME; Totaro R; Corea F; Marrosu MG; Confalonieri P; Cottone S; Trojano M; Zipoli V
    Front Neurol; 2021; 12():637615. PubMed ID: 33967938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioequivalence of intramuscular and subcutaneous peginterferon beta-1a: results of a phase I, open-label crossover study in healthy volunteers.
    Zhao Y; Chen K; Ramia N; Sahu S; Kumar A; Naylor ML; Zhu L; Naik H; Butts CL
    Ther Adv Neurol Disord; 2021; 14():1756286420975227. PubMed ID: 33628334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matching-adjusted comparisons demonstrate better clinical outcomes with SC peginterferon beta-1a every two weeks than with SC interferon beta-1a three times per week.
    Coyle PK; Shang S; Xiao Z; Dong Q; Castrillo-Viguera C
    Mult Scler Relat Disord; 2018 May; 22():134-138. PubMed ID: 29679749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial.
    Calkwood J; Cree B; Crayton H; Kantor D; Steingo B; Barbato L; Hashmonay R; Agashivala N; McCague K; Tenenbaum N; Edwards K
    BMC Neurol; 2014 Nov; 14():220. PubMed ID: 25424122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An update on Peginterferon beta-1a Management in Multiple Sclerosis: results from an interdisciplinary Board of German and Austrian Neurologists and dermatologists.
    Kolb-Mäurer A; Sunderkötter C; Kukowski B; Meuth SG;
    BMC Neurol; 2019 Jun; 19(1):130. PubMed ID: 31202258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
    Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
    Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient satisfaction with ExtaviPro™ 30G, a new auto-injector for administering interferon β-1b in multiple sclerosis: results from a real-world, observational EXCHANGE study.
    Hoffmann FA; Trenova A; Llaneza MA; Fischer J; Lus G; von Bredow D; Lara N; Lam E; Van Hoef M; Bakshi R
    BMC Neurol; 2017 Aug; 17(1):156. PubMed ID: 28793876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peginterferon beta-1a reduces disability worsening in relapsing-remitting multiple sclerosis: 2-year results from ADVANCE.
    Newsome SD; Kieseier BC; Liu S; You X; Kinter E; Hung S; Sperling B
    Ther Adv Neurol Disord; 2017 Jan; 10(1):41-50. PubMed ID: 28450894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global Peginterferon Beta-1a Tolerability Management Best Practices: A Nurse-Focused Delphi Approach.
    White S; Harris C; Allan M; Chieffe C; Eelen P; Röder C; Mouzawak C; Naylor ML
    Neurol Ther; 2021 Jun; 10(1):251-263. PubMed ID: 33761099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient satisfaction following transition from the original to the new formulation of subcutaneous interferon beta-1a in relapsing multiple sclerosis: a randomized, two-arm, open-label, Phase IIIb study.
    Camu W; Hadjout K; Latour S; Pöhlau D; Masri S
    Patient Prefer Adherence; 2010 May; 4():127-33. PubMed ID: 20517473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
    Hernandez L; Guo S; Kinter E; Fay M
    J Med Econ; 2016 Jul; 19(7):684-95. PubMed ID: 26947984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
    Calabresi PA; Kieseier BC; Arnold DL; Balcer LJ; Boyko A; Pelletier J; Liu S; Zhu Y; Seddighzadeh A; Hung S; Deykin A;
    Lancet Neurol; 2014 Jul; 13(7):657-65. PubMed ID: 24794721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients transitioning from non-pegylated to pegylated interferon beta-1a have a low risk of new flu-like symptoms: ALLOW phase 3b trial results.
    Naismith RT; Hendin B; Wray S; Huang D; Gaudenzi F; Dong Q; Sperling B; Mann M; Werneburg B
    Mult Scler J Exp Transl Clin; 2019; 5(1):2055217318822148. PubMed ID: 30729026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study.
    Beer K; Müller M; Hew-Winzeler AM; Bont A; Maire P; You X; Foulds P; Mårlind J; Curtius D
    BMC Neurol; 2011 Nov; 11():144. PubMed ID: 22074056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous Interferon Beta Therapy in Multiple Sclerosis Patients - Characterization of Injection Site Reactions and Flu-Like Symptoms in a Daily Practice Setting - Results from the Non-Interventional Study PERFECT.
    Kukowski B; Rehberg-Weber K; Taipale K; Kowalik A; Oschmann P
    Patient Prefer Adherence; 2021; 15():1091-1100. PubMed ID: 34079229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matching-adjusted comparisons demonstrate better clinical outcomes in patients with relapsing multiple sclerosis treated with peginterferon beta-1a than with teriflunomide.
    Newsome SD; Mokliatchouk O; Castrillo-Viguera C; Naylor ML
    Mult Scler Relat Disord; 2020 May; 40():101954. PubMed ID: 32078948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis.
    Hernandez L; Guo S; Toro-Diaz H; Carroll S; Syed Farooq SF
    J Med Econ; 2017 Mar; 20(3):228-238. PubMed ID: 27730845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peginterferon beta-1a for the treatment of relapsing multiple sclerosis: A case series.
    Hendin BA
    Mult Scler Relat Disord; 2018 Nov; 26():33-36. PubMed ID: 30216756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peginterferon beta-1a was associated with high adherence and satisfaction in patients with multiple sclerosis in a German real-world study.
    Menge T; Rehberg-Weber K; Taipale K; Nastos I; Jauß M
    Ther Adv Neurol Disord; 2021; 14():17562864211000461. PubMed ID: 33796146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.